Mitochon Pharmaceuticals Website, Blog & Press Pages

Mitochon Pharmaceuticals Website, Blog & Press Pages - aVenture

Mitochon Pharmaceuticals - Library

mitochonpharma.comCrawled Oct 15, 2026

6 pages

2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington’s disease » Mitochon Pharmaceuticals/news/dnp-improves-motor-function
Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the first exon of the gene huntingtin. There is no treatment to
DNP, mitochondrial uncoupling, and neuroprotection: A little dab’ll do ya » Mitochon Pharmaceuticals/news/dnp-mitochondrial-uncoupling-neuroprotection
Recent findings have elucidated roles for mitochondrial uncoupling proteins (UCPs) in neuronal plasticity and resistance tometabolic and oxidative stress.
Fifteen Small Businesses that are Making a Splash in the Big City » Mitochon Pharmaceuticals/news/fifteen-small-businesses-making-splash-big-city
Mitochon’s mission is to bring forward meaningful drugs that work at the root of insidious neurological diseases. By harnessing the power of the mitochondria,
Mitochon Pharmaceuticals Raises $1.6M for Clinical Stage Development » Mitochon Pharmaceuticals/news/mitochon-pharmaceuticals-raises-1-6m-clinical-stage-development
Blue Bell, Pennsylvania (BUSINESS WIRE)—Mitochon Pharmaceuticals today announced completion of its second year of funding with a total investment of $1.6

3 pages

Board of Directors » Mitochon Pharmaceuticals/company/board-of-directors
Wolfgang Baiker was interim CEO at Adrenomed AG and previously spent more than 30 years at Boehringer Ingelheim. He served as president and CEO of Boehringer Ingelheim USA from January 2018.
Management/company/management
Robert Alonso, founder and CEO, has 25 years of experience at large pharmaceutical and small biotech companies. He founded Ceptaris Therapeutics, raised over $40 million in venture capital, and led its program through phase III testing and an NDA filing.
Scientific Advisors & Collaborators » Mitochon Pharmaceuticals/company/scientific-advisors-collaborators
Dr. Andrew Feigin has more than 20 years of experience in Huntington’s disease clinical research. He participated in the Venezuela HD project and served as a site principal investigator on more than 30 clinical trials for Huntington’s and Parkinson’s diseases.

2 pages

Company/company
Mitochon aims to develop drugs that modulate mitochondrial physiology to attenuate disease progression.
Investors/company/investors
Mitochon is an early-stage biopharmaceutical company.

1 page

Homepage/
Mitochon Pharmaceuticals is a clinical-stage biotech company developing mitochondria-targeting drugs for serious diseases with unmet medical needs, including ALS, Huntington’s disease, progressive multiple sclerosis, traumatic brain injury and Alzheimer’s disease.

1 page